Ligand Pharmaceuticals Completes $739M Acquisition of XOMA Royalty

Key Facts

In a move that strengthens its position as a leading aggregator of biotechnology royalties, Ligand Pharmaceuticals has finalized its acquisition of XOMA Royalty Corporation. The transaction was completed in cash at $39.00 per share, representing a total equity value of approximately $739 million. This acquisition integrates more than 100 development and commercial-stage assets into Ligand's portfolio, bringing its total biopharmaceutical royalty assets to over 200.

This merger occurs amid a broader healthcare trend toward consolidating income-generating assets, as firms like Royalty Pharma (RPRX) compete for stable cash flows from approved therapies. Per market data, the inclusion of XOMA's assets provides Ligand with immediate access to seven new commercial products, aligning with the company's strategy to drive long-term growth by diversifying revenue streams away from direct R&D risks.

Operationally, investors are watching how this expansion will impact future cash flows, though specific price levels for LGND are currently unavailable. Looking ahead at the economic calendar, the release of the FOMC Minutes on July 8, 2026, remains a key catalyst that could influence financing costs for future M&A activity within the biotech sector.